Researchers at the University of California, Berkeley have identified a compound that increased the amount of energy the body uses rather than simply reducing how much food is eaten, according to findings published in Science Advances. The compound, 5-tetradecyloxy-2-furoic acid or TOFA, was first discovered in the 1970s.
Everything reported here was done in mice, and the researchers say TOFA's effectiveness and safety have not yet been established in humans. That caveat matters more than usual in this story, because the appeal of the result is precisely the thing that is hardest to carry across species.
Why muscle loss is the opening
GLP-1 drugs sold as Ozempic, Wegovy, Mounjaro and Zepbound work almost entirely by cutting appetite and food intake, which the researchers note can raise the risk of inadequate nutrition and loss of muscle mass. Over time, losing too much muscle can contribute to weakness and frailty, and that is the gap the Berkeley team went after.
"Body weight responds to two levers: taking in fewer calories, or spending more energy," said Anders Naar, professor of metabolic biology and nutrition at Berkeley and senior author. "GLP-1s work almost entirely on the first, so we went after the second."
Key results
In obese mice, treatment increased energy expenditure by as much as 18%, without the animals becoming more physically active or running a higher body temperature. Weight came off primarily as body fat, with no significant loss of lean muscle mass, alongside improved insulin sensitivity, lower triglycerides and improved characteristics of fatty liver disease.
TOFA belongs to a class called ACC inhibitors, several of which have reached mid-stage trials without approval, often because they raised blood triglycerides. This one did not, which the team attributes to its additional activation of the PPAR-alpha and PPAR-delta receptors.
Limitations
All findings come from animal studies, and scientists have not established whether the compound is safe or effective in people. Whether the same metabolic improvements appear in humans, and whether they would offer any real advantage over existing medications, remains untested.
A combination, not a replacement
Paired with semaglutide or tirzepatide in mice, TOFA produced better results on weight, glucose, insulin and triglycerides than either treatment alone. The team has founded a company, ReRx Therapeutics, to push the work forward, and frames the compound as complementary rather than a substitute.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.